Table 4:

Summary of ongoing/resulted DNA/RNA based vaccine trials for invasive HPV-associated malignancies

Vaccine	Vector	Antigen	Disease	Study	Results
MEDI-0457 (previously INO-3112)	VGX-3100 plasmid and INO-9012 plasmid	Modified E6 and E7 peptides + IL12	HPV+ HNSCC	Phase I/II trial of MEDI-0457 with durvalumab in ecurrent/metastatic HPC+ HNSCC	Pending (NCT03162224)
			HPV+ OPC*	Phase II trial of observation vs durvalumab vs MEDI-0457 + durvalumab in high risk HPV+ OPC	Pending (NCT04001413)
			HPV+ tumors	Phase II trial of MEDI-0457 + durvalumab in recurrent/metastatic HPV+ tumors	Pending (NCT03439085)
			HPV+ HNSCC	Phase I/II of concurrent INO-3112 delivered by electroporation with surgery or chemoradiation	Pending (NCT02163057)
			Cervix	Phase I/II of INO-3112 delivered by electroporation following chemoradiation or in recurrent setting	Pending (NCT02172911)
GX-188E	Pgx27 plasmid	HPV16 and 18 E6 and E7 + FLT3	Cervix (97)	Phase II study of pembrolizumab + GX-188E in recurrent cervical cancer	11/26 patients with response by RECIST, 4 complete at 24 weeks (NCT03444376)
VB10.16	Proprietary	HPV 16 E and E7	HPV16+ Cervix	Phase II study of atezolizumab + VB10.16 in recurrent HPV16+ cervical cancer	Pending (NCT04405349)
HARE-40	No vector	HPV mRNA + anti-CD40	HPV+ tumors	Phase I/II study of HARE-40 in upfront OPC in IA arm and recurrent HPV+ tumors in IB arms	Pending (NCT03418480)
BNT113	No vector	HPV16 E6 & E7	HPV+ OPC*	Randomized study of Pembrolizumab +/− BNT113 in CPS >1 pts	Pending (NCT04534205)

^*OPC: Oropharyngeal cancer